Our Team
The organization continually enhances operational and quality frameworks, empowering its team to ensure absolute customer satisfaction through rigorous validation of products and processes. With well-equipped facilities and a commitment to automated workflows where beneficial, the company maintains stringent quality standards upheld by a competent and innovative team.
Board Of Directors
The Board of Directors will oversee the company's strategic direction, organizational structure, and administrative functions.
David Goodman
Board member
James Gale
Executive Chairman Of The Board
Venkat Krishnan
Board member
James Gale
Chairperson Of The Board Of Bionpharma
Richard Van Duyne
Board member
James Gale
Chairperson Of The Board Of Bionpharma
Carole Ben-Maimon, M.D.
President And Chief Executive Officer
James Gale
Chairperson Of The Board Of Bionpharma
Executive Team
The leadership has the responsibility of managing the business operations of Bionpharma.
Venkat Krishnan
Board member
Lavesh Samtani, Esq.
EVP Business Development and General Counsel
Gaurav Mehrotra
CFO & EVP Commercial Operations
Phanindranath "Nath" Punji
EVP Supply Chain & Projects
Investors
Pharma Science
Our other strategic partner is Pharmascience Inc. Founded in 1983, Pharmascience is a leading manufacturer of generic drugs in a wide range of therapeutic categories. They are a privately owned company with technologically sophisticated operations designed to satisfy customer expectations for quality products and responsive service . Pharmascience’s R & D laboratory and production facilities are located in Montreal, Quebec and their Canada-wide customer base includes pharmacists, drug wholesalers and major retailers. Pharmacience is the largest pharmaceutical employer in Quebec, Canada, with 1,300 employees and the third largest generic pharmaceutical company in Canada and third largest pharmaceutical company in Canada by number of prescriptions. Pharmascience enjoys a diversified portfolio of over 340 product families, both prescription and OTC with sales in more than 60 countries and is one of the largest providers of generic single-source products.
Athyrium
LP: Athyrium Capital Management LP is an SEC-registered asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Managing funds with over $1.7 billion of committed capital, including a $1.2 billion fund recently closed in May 2015 , Athyrium invests across all healthcare verticals including biopharmaceuticals, medical devices and products, and healthcare services. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes, including private equity, public equity, fixed income, royalties, and other structured securities. The firm’s investors include public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds.
Signet
Signet Healthcare partners was founded in 1998 with the establishment of the Corporate Opportunities Funds. Since 1998, they have organized three funds and completed investments in approximately 35 companies. The team is comprised of six professionals with principal offices in New York City. This team brings over 100 years experience of collective healthcare experience in the specialty pharmaceutical, medical device, private equity and investment banking businesses. For the past sixteen years, Signet Healthcare has maintained its dedicated focus to diversified healthcare investing – primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and the pharma services industries.